Table 3.
Logistic regression model for prevalent melanoma in participants enrolled in the ASPREE trial (pretrial self-reported cases)a
| Covariate | PRS as continuous variable (per SD) |
PRS as categorical variable (low, medium, high) |
||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Sex, female | 0.82 (0.69 to 0.98) | .03 | 0.82 (0.69 to 0.98) | .02 |
| Family history | 2.36 (1.61 to 3.35) | <.001 | 2.38 (1.63 to 3.37) | <.001 |
| PRS per SD | 1.55 (1.42 to 1.69) | <.001 | — | — |
| Low PRS, 0%-20% (n = 64) | — | — | 1.00 (Reference) | — |
| Medium PRS, 20%-80% (n = 349) | — | — | 1.88 (1.41 to 2.56) | <.001 |
| High PRS, 80%-100% (n = 213) | — | — | 3.66 (2.69 to 5.05) | <.001 |
a
A total of 120 incident melanomas occurred during the ASPREE trial, of which 98 had no pre-trial (prevalent) melanoma. A total of 528 participants had self-reported prevalent melanoma at baseline. In total: 626 participants had melanoma. ASPREE = ASPirin in Reducing Events in the Elderly; CI = confidence interval; OR = odds ratio; PRS = polygenic risk score.